NASDAQ: LTRN - Lantern Pharma Inc.

Yield per half year: +0.5714%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Lantern Pharma Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

more details
In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-06-11
ISIN US51654W1018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lanternpharma.com
Цена ао 3.65
Change price per day: -0.2833% (3.53)
Change price per week: +36.43% (2.58)
Change price per month: -7.37% (3.8)
Change price per 3 month: +0.8596% (3.49)
Change price per half year: +0.5714% (3.5)
Change price per year: -41.04% (5.97)
Change price per 3 year: -47.7% (6.73)
Change price per year to date: +9.66% (3.21)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.08 9
P/E 0 0
EV/EBITDA -1.27 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % -36.57 0
ROE, % -39.02 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0132 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 557.78 10
Yield EPS, % 276.99 10
Total: 8
More

Institutions Volume Share, %
Vanguard Group Inc 365334 3.4
NewEdge Advisors, LLC 165972 1.55
Geode Capital Management, LLC 95036 0.88
CM Management, LLC 80000 0.74
Carlson Capital. L.P. 60000 0.56
Commonwealth Equity Services, LLC 58848 0.55
Renaissance Technologies, LLC 43800 0.41
Redmond Asset Management, LLC 40662 0.38
Horizon Kinetics Asset Management LLC 28791 0.27
State Street Corporation 27752 0.26



Head Job title Payment Year of birth
Mr. Panna Sharma PH.D. President, CEO & Director 684.38k 1971 (54 years)
Mr. David R. Margrave CFO & Secretary 442.68k 1961 (64 years)
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant 283.24k 1955 (70 years)
Nicole Leber Investor Relations Associate, Finance & Administrative Coordinator N/A
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor N/A
Mr. Ernest Kitt B.S., M.S Head of Clinical Operations N/A
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics

Address: United States, Dallas. TX, 1920 McKinney Avenue - open in Google maps, open in Yandex maps
Website: https://www.lanternpharma.com